Abstracts presented at ASCO 2017: drug re-challenge and pharmacoeconomics
Immunotherapy: changing the landscape of cancer treatment
S-TRAC Phase III trial of sunitinib as adjuvant therapy in high-risk renal cell cancer patients
OPTiM trial update: T-VEC for the treatment of melanoma
Immuno-oncology agents plus tyrosine kinase inhibitors?